TGTX — TG Therapeutics, Inc.
Is TGTX overbought or oversold? Here is the current MarketMoodz read.
TG Therapeutics, Inc. (TGTX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $62.71. The rating moved from Oversold to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$62.71
- Last changeMoved from Oversold to Neutral on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
TG Therapeutics, Inc. (TGTX) is a clinical‑stage specialty biopharma with binary clinical and regulatory catalysts that will primarily drive near‑term performance. Current market conditions show consolidation and limited directional conviction, providing little immediate sector tailwind for small specialty names; the company’s trajectory depends heavily on upcoming program readouts, cash‑management decisions, and potential partnership or M&A activity. Given limited public financial detail, high clinical execution risk, and competitive pressures, outcomes range from meaningful upside on positive development news to material downside if trials or financing plans falter.
Key factors
- Clinical-stage pipeline with potential near- to mid-term binary catalysts (trial readouts / regulatory actions) that could re-rate the equity
- Market environment showing consolidation and selective growth support; limited volatility reduces short-term directional conviction
- Relative lack of large-cap defensive flows into small specialty biotech reduces near-term tailwind versus big pharma consolidators
- Potential strategic optionality (partnerships or M&A interest) given sector consolidation trends among large pharma acquiring specialty franchises
- Unclear public financials and cash runway visibility for ongoing development spend increase dependence on financing or partnerships
Risks
- Trial failure, negative safety signals, or missed endpoints that would materially impair near-term value
- Regulatory setbacks or requests for additional data leading to delays and higher development costs
- Cash runway constraints forcing dilutive financing or unfavorable partnering terms
- Competitive pressure from larger, better‑funded players in overlapping therapeutic areas
- Low social and research visibility increases susceptibility to liquidity-driven volatility and wide intraday moves
- Macro/regulatory shifts (e.g., payer/regulatory changes) that could compress pricing or market access for relevant therapies
See today's live rating, score and targets
Members see the live hourly rating for TGTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.